Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis.

Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R.

Hepatogastroenterology. 2012 Jun;59(116):960-4. doi: 10.5754/hge12189.

PMID:
22580643
2.

Activation of murine macrophages.

Fortier AH.

Curr Protoc Immunol. 2001 May;Chapter 14:Unit 14.4. doi: 10.1002/0471142735.im1404s11.

PMID:
18432722
3.

Isolation of murine macrophages.

Fortier AH, Falk LA.

Curr Protoc Immunol. 2001 May;Chapter 14:Unit 14.1. doi: 10.1002/0471142735.im1401s11.

PMID:
18432719
4.

Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction.

Plum SM, Vu HA, Mercer B, Fogler WE, Fortier AH.

Immunopharmacol Immunotoxicol. 2004 Feb;26(1):29-41.

PMID:
15106730
6.

Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile.

Sim BK, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, O'Reilly MS, Tomaszewski JE, Fortier AH.

Angiogenesis. 1999;3(1):41-51.

PMID:
14517443
7.

Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.

Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, Vu H, Plum SM, Nelson BJ.

Prostate. 2003 Aug 1;56(3):212-9.

PMID:
12772191
8.

Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development.

Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE, Fortier AH.

Vaccine. 2000 Dec 8;19(9-10):1294-303.

PMID:
11137269
9.

RESPONSE: re: antiangiogenic activity of prostate-specific antigen

Fortier AH, Grella DK, Nelson BJ, Holaday JW.

J Natl Cancer Inst. 2000 Feb 16;92(4):345A-346. No abstract available.

PMID:
10675386
10.

Antiangiogenic activity of prostate-specific antigen.

Fortier AH, Nelson BJ, Grella DK, Holaday JW.

J Natl Cancer Inst. 1999 Oct 6;91(19):1635-40.

PMID:
10511590
11.

A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer.

Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA.

Cancer Res. 1997 Apr 1;57(7):1329-34.

12.

Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth.

Fortier AH, Leiby DA, Narayanan RB, Asafoadjei E, Crawford RM, Nacy CA, Meltzer MS.

Infect Immun. 1995 Apr;63(4):1478-83.

13.

Heat stress alters the virulence of a rifampin-resistant mutant of Francisella tularensis LVS.

Bhatnagar NB, Elkins KL, Fortier AH.

Infect Immun. 1995 Jan;63(1):154-9.

14.
15.

Nitric oxide-independent killing of Francisella tularensis by IFN-gamma-stimulated murine alveolar macrophages.

Polsinelli T, Meltzer MS, Fortier AH.

J Immunol. 1994 Aug 1;153(3):1238-45.

PMID:
8027551
16.

Life and death of an intracellular pathogen: Francisella tularensis and the macrophage.

Fortier AH, Green SJ, Polsinelli T, Jones TR, Crawford RM, Leiby DA, Elkins KL, Meltzer MS, Nacy CA.

Immunol Ser. 1994;60:349-61. Review. No abstract available.

PMID:
8251580
17.

Macrophage activation: a riddle of immunological resistance.

Crawford RM, Leiby DA, Green SJ, Nacy CA, Fortier AH, Meltzer MS.

Immunol Ser. 1994;60:29-46. Review.

PMID:
8251575
18.

T-cell-independent resistance to infection and generation of immunity to Francisella tularensis.

Elkins KL, Rhinehart-Jones T, Nacy CA, Winegar RK, Fortier AH.

Infect Immun. 1993 Mar;61(3):823-9.

20.

Immunotherapy of tularemia: characterization of a monoclonal antibody reactive with Francisella tularensis.

Narayanan RB, Drabick JJ, Williams JC, Fortier AH, Meltzer MS, Sadoff JC, Bolt CR, Nacy CA.

J Leukoc Biol. 1993 Jan;53(1):112-6.

PMID:
8426087
21.

Detection of Francisella tularensis in blood by polymerase chain reaction.

Long GW, Oprandy JJ, Narayanan RB, Fortier AH, Porter KR, Nacy CA.

J Clin Microbiol. 1993 Jan;31(1):152-4.

22.

Rapid generation of specific protective immunity to Francisella tularensis.

Elkins KL, Leiby DA, Winegar RK, Nacy CA, Fortier AH.

Infect Immun. 1992 Nov;60(11):4571-7.

23.

Introduction of Francisella tularensis at skin sites induces resistance to infection and generation of protective immunity.

Elkins KL, Winegar RK, Nacy CA, Fortier AH.

Microb Pathog. 1992 Nov;13(5):417-21.

PMID:
1297917
24.
25.

In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies.

Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA.

Infect Immun. 1992 Jan;60(1):84-9.

26.

Live vaccine strain of Francisella tularensis: infection and immunity in mice.

Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA.

Infect Immun. 1991 Sep;59(9):2922-8.

28.
29.
32.

Genetic control of systemic Leishmania major infection: identification of subline differences for susceptibility to disease.

Mock BA, Fortier AH, Potter M, Blackwell J, Nacy CA.

Curr Top Microbiol Immunol. 1985;122:115-21. No abstract available.

PMID:
4042673
33.

Immunoprophylaxis in BALB/c mice: a model for development of protection against primary and secondary infection with Leishmania major.

Mock BA, Fortier AH, Meltzer MS, Nacy CA.

Curr Top Microbiol Immunol. 1985;122:107-14. No abstract available.

PMID:
4042672
35.
36.
37.

Supplemental Content

Loading ...
Support Center